Linked Life Data

11092221

Source:http://linkedlifedata.com/resource/pubmed/id/11092221

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
4
pubmed:dateCreated
2001-2-14
pubmed:abstractText
Patients with advanced liver cirrhosis have a serious disturbance in their hemostasis system that leads to increased morbidity and mortality. The vitamin K-dependent clotting factors, especially factor VII, are markedly reduced in these patients. Present treatment modalities include fresh frozen plasma (FFP), vitamin K, and desmopressin. FFP has to be given in large volume and entails the risk of transmitting infectious agents. The introduction of recombinant activated factor VII (rFVIIa) has offered another treatment option for patients with liver cirrhosis and bleeding. The clinical experience with rFVIIa is reviewed. Management seems to be effective and safe and the concern that rFVIIa might activate the hemostasis system in these patients has not materialized. Administration of rFVIIa not only corrected the abnormal clotting tests in these patients but also allowed several invasive procedures without the complication of bleeding.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:issn
0094-6176
pubmed:author
pubmed:issnType
Print
pubmed:volume
26
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
437-8
pubmed:dateRevised
2008-11-21
pubmed:meshHeading
pubmed:year
2000
pubmed:articleTitle
Effectiveness of the recombinant factor VIIa in patients with the coagulopathy of advanced child's B and C cirrhosis.
pubmed:affiliation
Division of Gastroenterology and Hepatology, North Shore University Hospital, Manhasset, New York 11030, USA. deberns@banet.net
pubmed:publicationType
Journal Article, Review